[Cancer Management and Research] Researchers sought to quantify the effect of the measures taken to reduce transmission of the coronavirus on diagnosis and treatment of nasopharyngeal cancer.
EAT-10 and pain correlated to FOIS scores in patients with HNC for the evaluation of swallowing functionality and ingestion status, whereas other tests were found unnecessary.
The accelerated approval was based on data from a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic solid tumors with TMB-H who were enrolled in the open-label phase 2 KEYNOTE-158 trial.
Although APCD use improved lymphedema and facial swelling, participants in the treatment group reported no change in pain levels from baseline.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
[OncoTargets and Therapy] This review of the current practices in managing sinonasal mucosal melanoma discusses the significance of the multidisciplinary team approach in optimizing treatment, reducing costs, minimizing adverse events, and maximizing chance of cure.
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
The majority of patients enrolled in this study were unable to receive cisplatin due to an ear-related comorbidity.
